Angioplasty for the late stent thrombosis, the new technical challenge: A single centre experience

Goel, Pravin K.; Gill, Gursewak Singh

doi:10.1016/j.ijcard.2006.11.160

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14) Yet another study noted that the inadvertent interruption of clopidogrel therapy also can induce late stent thrombosis. 17) Dual antiplatelet therapy can prevent stent thrombosis, but withdrawal of any one agent could result in the cardiovascular events at any time.…”

Section: Discussionmentioning

confidence: 99%

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries

Ahn¹,

Cho²,

Kim³

et al. 2008

Korean Circ J

View full text Add to dashboard Cite

Late stent thrombosis is one of the most serious complications associated with morbidity and mortality after coronary drug-eluting stent implantation, and is mainly caused by the withdrawal of antiplatelet agents. We report our experience of late stent thrombosis simultaneously involving three different coronary arteries in a young male patient who was treated with three drug-eluting stents two years ago. The patient stopped taking antiplatelet agents for several days. The patient did not recover from cardiogenic shock, even after repeated ballooning with thrombus aspiration, intra-aortic balloon pumping, and temporary pacing during cardiopulmonary resuscitation.

show abstract

Section: Discussionmentioning

confidence: 99%

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries

Ahn¹,

Cho²,

Kim³

et al. 2008

Korean Circ J

View full text Add to dashboard Cite

show abstract

“…In this situation the risk of interrupting dual antiplatelet therapy seems to exceed the risk of bleeding, as it is well documented that untimely, premature withdrawal of dual antiplatelet therapy is the strongest predictor of subsequent stent thrombosis. 24,45,46 Other risk factors include renal failure, diabetes mellitus, low cardiac ejection fraction, and procedures involving bifurcation lesions. 24 However, surgery in closed cavities (brain, eye) cannot be carried out under dual antiplatelet therapy, as bleeding may either negate the benefits of surgery or endanger the patient's life, and the antiplatelet regime has to be modified.…”

Section: Type Of Surgerymentioning

confidence: 99%

Do percutaneous coronary interventions protect the surgical patient?

Howard-Alpe

Bono

Hudsmith

et al. 2008

Southern African Journal of Anaesthesia and Analgesia

View full text Add to dashboard Cite

The number of percutaneous coronary interventions (PCI) performed annually has increased rapidly over the last two decades. Coronary angioplasties are now commonly complemented with the insertion of coronary artery stents. Initially bare metal stents (BMS) were developed with drug-eluting stents (DES) subsequently being introduced. Drug-eluting stents reduce in-stent restenosis at the cost of prolonged anti-platelet therapy. While observational studies suggest that coronary artery bypass graft surgery protects against perioperative cardiac events in non-cardiac surgery, no such evidence exists for PCI. In order to prevent stent thrombosis, patients need to receive dual anti-platelet therapy (generally aspirin and clopidogrel) for four to six weeks with BMS, and at least one year with DES. Patients on dual anti-platelet therapy are at risk of severe bleeding during surgery. However, withdrawal of dual anti-platelet therapy is associated with the risk of stent thrombosis. The risk of cardiac complications seems to exceed the risk of bleeding, and maintenance of dual anti-platelet therapy is advocated whenever possible. Surgery in closed cavities (neurosurgery, intraocular surgery) necessitates the withdrawal of dual anti-platelet therapy. There is a significant risk of perioperative complications in patients who have DES, or recently inserted BMS, and consequently surgery should not be performed without a discussion involving the surgeon, cardiologist, anaesthetist, and the patient. IntroductionOver the past thirty years there have been major advances in the management of patients with coronary artery disease. These have included life style changes, recently complemented in some countries by the ban of smoking in public places, the development of drug strategies including beta-adrenoceptor blockers, angiotensin-converting enzyme inhibitors, statins, aspirin, thrombolysis and early myocardial revascularisation. Coronary artery bypass graft (CABG) surgery has also evolved. Internal mammary arteries and subsequently radial arteries have been utilised alone or in addition to saphenous vein grafts to revascularise the coronary circulation, and CABG surgery may be performed with or without cardiopulmonary bypass. Finally, there has been the rapid development of percutaneous coronary interventions. These advances resulted in a 65% decrease in the death rate among patients below the age of 65 over the period 1970-2002.

show abstract

Angioplasty for the late stent thrombosis, the new technical challenge: A single centre experience

Cited by 2 publications

References 7 publications

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries

Do percutaneous coronary interventions protect the surgical patient?

Contact Info

Product

Resources

About